175 related articles for article (PubMed ID: 30519357)
1. The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses.
Peng L; Liu ZL; Xu C; Tang LL; Liu X; Lin AH; Sun Y; Chen YP; Ma J
J Cancer; 2018; 9(23):4510-4520. PubMed ID: 30519357
[No Abstract] [Full Text] [Related]
2. A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma.
Wang BC; Shi LL; Fu C; Zhou HX; Zhang ZJ; Ding Q; Peng G
Medicine (Baltimore); 2019 Oct; 98(42):e17486. PubMed ID: 31626102
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma.
Xu YC; Chen KH; Liang ZG; Zhu XD
Front Oncol; 2022; 12():843675. PubMed ID: 35903695
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
[TBL] [Abstract][Full Text] [Related]
7. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis.
Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX
JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis.
Liang ZG; Lin GX; Ye JX; Li Y; Li L; Qu S; Liang X; Zhu XD
Asian Pac J Cancer Prev; 2018 May; 19(5):1397-1404. PubMed ID: 29802706
[TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
Cancer Sci; 2018 May; 109(5):1609-1616. PubMed ID: 29575438
[TBL] [Abstract][Full Text] [Related]
11. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.
Yuan JJ; Ding JW; Li JW; Hu RH; Gong D; Hu JL; Zhu KB; Liu Y; Ding YH; Wei JW; Zeng JL; Lu ZB; Yin WH; Ai SF; Zha GH; Zhang ZL; Zou R; Zeng L
BMJ Open; 2022 Aug; 12(8):e051594. PubMed ID: 36008072
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
13. Treatment Protocols in the Efficacy and Safety of Anti-EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta-Analysis.
Fang Y; Fan J; Yan C
Biomed Res Int; 2023; 2023():9477442. PubMed ID: 36794258
[TBL] [Abstract][Full Text] [Related]
14. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
[TBL] [Abstract][Full Text] [Related]
15. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis.
Lai L; Chen X; Zhang C; Chen X; Chen L; Tian G; Zhu X
Front Oncol; 2020; 10():610787. PubMed ID: 33665166
[TBL] [Abstract][Full Text] [Related]
17. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
19. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.
Chitapanarux I; Kittichest R; Tungkasamit T; Asakit T; Chomprasert K; Chakrabandhu S; Onchan W; Traisathit P
Curr Probl Cancer; 2021 Feb; 45(1):100620. PubMed ID: 32713518
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis.
Tang M; Jia Z; Zhang J
Eur Arch Otorhinolaryngol; 2021 May; 278(5):1545-1558. PubMed ID: 32700235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]